Pfizer and BioNTech’s Covid-19 and flu vaccine failed to meet a key goal in a late-stage trial, jeopardising a highly anticipated product that would help the drugmakers to compete in the post-Covid jab market.
The drugmakers, which co-produced their top selling Covid vaccine during the pandemic, are developing a combination shot to protect against both flu and Covid.
On Friday, Pfizer and BioNTech said their product tested on 18 to 64-year-olds gave a more effective immune response against influenza A strain than a licensed flu vaccine and was as effective against Covid as their existing product. But the vaccine was inferior in targeting the less prevalent influenza B strain. The shot was tested on more than 8,000 adults.
您已閱讀25%（731字），剩余75%（2220字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。